HIV Infections
Conditions
Keywords
HIV, antiretroviral, drug interaction, human immunodeficiency virus
Brief summary
The purpose of this study is to test whether there is a drug interaction between raltegravir (a medicine used to treat the human immunodeficiency virus or HIV) and antacids.
Detailed description
This study will determine if an interaction occurs between the HIV medicine raltegravir and an antacid. A prior study found an interaction with another medicine like raltegravir called elvitegravir and an antacid. The elvitegravir levels were reduced by half. The same interaction may occur with raltegravir and an antacid based on the structure of this medicine and how it works. When the levels of HIV medications are reduced, people with HIV can fail their treatment. The virus can multiply when the drug levels are too low and the medications can stop working. We need to be sure that antacids will not cause this problem with raltegravir.
Interventions
DRUGraltegravir
raltegravir 400mg orally once
DRUGantacid
aluminum, magnesium, simethicone-containing antacid 30mL orally once
Sponsors
University of Colorado, Denver
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Absence of HIV-1 infection as documented by any licensed ELISA test kit within 21 days prior to study entry. * Age greater than or equal to 18 but less than or equal to 60 years. * Ability and willingness to give written informed consent. * Within 30% (+/-) of ideal body weight and total body weight of ≥ 50 kg. * Hematology, Metabolic Profile, Renal, and Hepatic Function tests all within normal limits. * Creatine kinase (CK) less than 3 times the upper limit of normal
Exclusion criteria
* Pregnancy or breast-feeding. * Women and men of reproductive potential who are actively engaging in sexual activity or assisted reproductive technology with the intent of pregnancy. * Allergy/sensitivity to raltegravir. * Allergy/sensitivity to antacids. * Active drug or alcohol abuse or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements. While on study, subjects will be instructed not to consume alcohol for 48 hours prior the screening visit, and for the 24 hours preceding the intensive pharmacokinetic (PK) study visits and for 24 hours following the completion of the study visits. * Any medical condition that, in the opinion of the investigator, would interfere with the subject's ability to participate in this protocol. * Participation in any investigational drug studies within 30 days prior to study entry. * History of or active cardiovascular, renal, hematologic, hepatic, neurologic, gastrointestinal, psychiatric, endocrine, or immunologic disease(s). This is inclusive of chronic illnesses such as hypertension, coronary artery disease, arthritis, diabetes, any chronic gastrointestinal conditions that might interfere with drug absorption. * Use of investigational, prescription, and over-the-counter medications within 14 days of study entry with the following exceptions: aspirin, acetaminophen, ibuprofen, and oral contraceptives
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Raltegravir AUC with and without an antacid | 0-48 hours |
Secondary
| Measure | Time frame |
|---|---|
| Raltegravir Cmax with and without an antacid | 0-48 hours |
Countries
United States
Outcome results
None listed